CN105663184A - Livestock compound medicine containing garden balsam stem and florfenicol - Google Patents

Abstract

The invention relates to a livestock compound medicine containing garden balsam stem and florfenicol, which is prepared from the following raw materials in part by weight: 5 to 30 parts of florfenicol and 10 to 170 parts of garden balsam stem. After the raw materials are uniformly mixed, the mixture is prepared into powder, tablets, oral liquid or granules; the livestock compound medicine is added into a livestock feed according to a feed additive amount of 0.1 to 7g/kg to carry out feeding; drug resistance of bacteria to antibacterial drug can be reversed, so that a treatment effect of the antibacterial drug is improved, drug cost and drug residues are greatly reduced, higher economic benefits are created for farmers, and food safety of people is guaranteed.

Description

A kind of poultry compound medicine containing Herba speranskiae tuberculatae and florfenicol

The denomination of invention that the present invention is application on 04 15th, 2014 is " a kind of compound treating poultry coli-infection disease ", and application number is the divisional application of 201410150091.7.

Technical field

The invention belongs to poultry coli-infection treatment technology field, particularly relate to a kind of poultry compound medicine containing Herba speranskiae tuberculatae and florfenicol.

Background technology

Escherichia coli are common conditioned pathogens, also it is a kind of disease often sent out, it can former have been carried out the coffin upon burial the multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis, also can secondary or mixed send out in virosis, cause huge economic loss to aquaculture. The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs preventing and treating this disease, along with cultivation scale intensive degree is more and more big, medication is more and more spread unchecked, its Resistant strain is more and more many, and the report about Drug Resistance of E. coli is also more. Research confirms, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be hydrolyzed beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose antibacterial activity. ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and is crossing drug resistant to aminoglycoside, quinolones and sulfonamides, only to carbapenems, a mould alkene class medicaments insensitive. Many documents it have been reported that colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to comparatively pay close attention to. Inventor has carried out the detection of food animal source pathogenic bacterium ESBLs, extraction, enzyme recently to researchs such as the enzyme protection effects that presses down of antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; the colibacillary drug sensitive test of part ESBLs is shown, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain. It addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in serious multidrug resistant. Inventor is separated to resistance to fosfomycin in producing ESBLs bacterial strain and produces the escherichia coli of fosA3 drug resistant gene, more strengthens the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and brings bigger economic loss to production, and increases poultry drug residue risk. Therefore, actual production is needed badly a kind of to regardless of whether the escherichia coli of drug resistance can have a medicine of better therapeutical effect, and treatment course for the treatment of can be shortened, reduce mortality rate, reduce economic loss and reduce drug residue, creating higher economic benefit for raiser, also ensure that the mankind's is healthy and safe.

Summary of the invention

The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Herba speranskiae tuberculatae and florfenicol, it can kill antibacterial quickly, overcome the weak curative effect that antimicrobial drug treatment causes due to drug resistance problems, the defect that consumption is big, residual is high and cost is high, it is to avoid simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.

For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing Herba speranskiae tuberculatae and florfenicol, be made up of the raw material of following weight portion: florfenicol 5-30 part, Herba speranskiae tuberculatae 10-170 part.

The dosage form of this compound is powder, tablet, oral liquid or granule.

The preparation method of above-mentioned compound medicine, pulverized Herba speranskiae tuberculatae 60 mesh sieves, then mixed with pulverous antimicrobial drug, prepared into powder, tablet, oral liquid or granule according to a conventional method.

For the drug resistance problems that current poultry coli-infection exists, inventor utilizes Guangxi Special Traditional Chinese Medicine Herba speranskiae tuberculatae and antimicrobial drug composition compound. Research proves, after adding Herba speranskiae tuberculatae in antimicrobial drug, it is possible to the reverse bacterial drug resistance to antimicrobial drug, thus improving the therapeutic effect of antimicrobial drug. According to a conventional method this compound is made powder, tablet, oral liquid or granule, add in animal and fowl fodder according to the addition of 0.1-7g principal agent/kg feedstuff and feed, drug cost and drug residue can be greatly reduced, create higher economic benefit for raiser, also ensure that food safety simultaneously.

Detailed description of the invention

One, the Herba speranskiae tuberculatae drug resistance inversion Effect study to antimicrobial drug

Antimicrobial drug itself has the colibacillary effect for the treatment of, but the escherichia coli owing to producing ESBLs drug resistant gene have stronger drug resistance, cause antimicrobial drug not show good therapeutic effect in normal using dosage situation.

In order to verify the Herba speranskiae tuberculatae drug resistance inversion effect to antimicrobial drug, 96 orifice plates adopt microtest tube doubling dilution, first determine the antimicrobial drug minimal inhibitory concentration of e. coli strains and the Herba speranskiae tuberculatae subinhibitory concentration to producing ESBLs and fosA3 drug resistant gene e. coli strains to producing ESBLs and fosA3 drug resistant gene, then add the Herba speranskiae tuberculatae of subinhibitory concentration in the medium and reuse microtest tube doubling dilution and cultivate the minimal inhibitory concentration measuring antimicrobial drug; Utilize continuous passage method, in the culture medium added with same subinhibitory concentration Herba speranskiae tuberculatae and same concentration antimicrobial drug, product ESBLs and fosA3 drug resistant gene e. coli strains is carried out Secondary Culture, until the antimicrobial drug minimal inhibitory concentration observed diminishes more than 4 times compared with before going down to posterity, can be judged as that antibacterial medical instrument is had drug resistance inversion effect by Herba speranskiae tuberculatae. Result of the test statistics is as shown in table 1:

Table 1 subinhibitory concentration (0.25g/mL) Herba speranskiae tuberculatae goes down to posterity and causes the change (μ g/mL) producing ESBLs and fosA3 escherichia coli Western medicine MIC.

As seen from the above table, the minimal inhibitory concentration of antibiotic-resistance E. coli is all reduced more than 4 times by antimicrobial drug, namely can determine whether it is that Herba speranskiae tuberculatae has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.

Two, the application example of compound of the present invention

Prepare embodiment 1-embodiment 4 in accordance with the following methods: after Herba speranskiae tuberculatae was pulverized 60 mesh sieves, based on raw material, then with pulverous antimicrobial drug ratio by weight put in blender mix, prepare into preparation according to a conventional method.

The formula of table 2 embodiment 1-4 and product

The compound product of the embodiment 1-4 gained efficacy experiment to the piglet diarrhea of 50 ages in days:

Clinical symptoms: pig farm, Guigang, Guangxi, 50 age in days piglets, this swinery, after wean is turn-taked, starts diarrhoea occur, draws watery stools, feces contains indigested feedstuff, pig material feeding but be exactly not long, serious individually diarrhea of pigs dehydration is dead, it does not have symptoms of emesis occur, raiser uses multi-medicament, and ideal effect does not all occur in treatment.

Cut open inspection pathological changes: after cuing open inspection, Intestinum Sus domestica wall is belittled, and especially small intestinal rear end and colon site, intestinal mucosa comes off, and intestinal wall is congested, hemorrhage.

Laboratory diagnosis: take pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, it is seen that red gram negative bacilli; Tentatively it is judged as bacillus coli. Being cultivated by escherichia coli, biochemical test differentiates, it is judged that Infection in Piglets is bacillus coli, pcr amplification, it was demonstrated that produce the ESBLs drug resistant gene and the fosA3 drug resistant gene that there are OXA type.

Test therapeutic regimen: morbidity swinery divides 6 groups of administrations, first group is administered according to the addition of 3g/kg feedstuff by embodiment 1, second group is administered according to the addition of 4g/kg feedstuff by embodiment 2,3rd group is administered according to the addition of 0.4g/kg feedstuff by embodiment 3, and the 4th group is administered according to the addition of 2g/kg feedstuff by embodiment 4; 5th group is administered according to the addition of 0.3g/kg feedstuff by florfenicol powder, and the 6th group is administered according to the addition of 3.8g/kg feedstuff with the thick powder of Herba speranskiae tuberculatae; Above six groups of therapeutic regimens all persistently use 5 days.

Result of use is fed back: after first group to the 4th group medication 2 days, swinery no longer draws watery stools, formed stools, no longer contain feedstuff, be continuing with 3 days in feces, swinery recovery from illness; After 5th group of medication 2 days, swinery is still unhealthy, is continuing with 3 days, substantially gets well, but still draws individually pasty state feces, but after drug withdrawal 3 days, recurrence occurs in swinery; After 6th group of medication 2 days, swinery, without remarkable improvement, is continuing with 3 days, and swinery continues to have loose bowels, and also ratio is more serious individually for all the other. Visible, swinery curative effect is better than folk prescription florfenicol and folk prescription Herba speranskiae tuberculatae by the compound containing Herba speranskiae tuberculatae.

Claims (1)

1. the poultry compound medicine containing Herba speranskiae tuberculatae and florfenicol, it is characterised in that be made up of the raw material of following weight ratio: florfenicol 5-30 part, Herba speranskiae tuberculatae 10-170 part.